Literature DB >> 1983826

Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma.

M Tada1, M Omata, M Ohto.   

Abstract

Most pancreatic adenocarcinomas are known to have ras gene (oncogene) mutations. The site of the mutations is localized in codon 12 of K-ras gene. Such high incidence and localization of the ras gene mutations have not been observed in any other human malignancies. Polymerase chain reaction and direct sequencing method enabled us to analyze DNA sequence around codon 12 of K-ras gene in small quantities of specimens obtained from needle biopsies and aspirate samples for pathological diagnosis. All the materials obtained from 12 patients with pancreatic adenocarcinoma showed the mutations, whereas those obtained from 6 patients with chronic pancreatitis showed no mutations. In several cases using the mutations of K-ras gene as a marker, this analysis supplemented conventional pathology and cytology in making the diagnosis of pancreatic adenocarcinoma. The analysis of ras-gene mutations was useful for the clinical diagnosis of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1983826     DOI: 10.1016/0016-5085(91)90606-l

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  39 in total

1.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 3.  Primary malignant fibrous histiocytoma of the pancreas: a case with K-ras mutation and a review of the literature.

Authors:  Tomotaka Akatsu; Masashi Tsugita; Seiichi Ro; Kaori Kameyama; Masaki Kitajima
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 4.  K-ras mutation and pancreatic adenocarcinoma.

Authors:  C Caldas; S E Kern
Journal:  Int J Pancreatol       Date:  1995-08

Review 5.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

6.  Quantitative analysis of ras gene mutation in pancreatic juice for diagnosis of pancreatic adenocarcinoma.

Authors:  M Tada; T Teratani; Y Komatsu; T Kawabe; Y Shiratori; M Omata
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

7.  Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique.

Authors:  D B Evans; M L Frazier; C Charnsangavej; R L Katz; L Larry; J L Abbruzzese
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

8.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.

Authors:  Takeshi Ogura; Kenji Yamao; Kazuo Hara; Nobumasa Mizuno; Susumu Hijioka; Hiroshi Imaoka; Akira Sawaki; Yasumasa Niwa; Masahiro Tajika; Shinya Kondo; Tsutomu Tanaka; Yasuhiro Shimizu; Vikram Bhatia; Kazuhide Higuchi; Waki Hosoda; Yasushi Yatabe
Journal:  J Gastroenterol       Date:  2012-09-15       Impact factor: 7.527

9.  Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.

Authors:  J Kim; H A Reber; S M Dry; D Elashoff; S L Chen; N Umetani; M Kitago; O J Hines; K K Kazanjian; S Hiramatsu; A J Bilchik; S Yong; M Shoup; D S B Hoon
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

10.  Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

Authors:  Jatin Roper; Mark J Sinnamon; Erin M Coffee; Peter Belmont; Lily Keung; Larissa Georgeon-Richard; Wei Vivian Wang; Anthony C Faber; Jihye Yun; Ömer H Yilmaz; Roderick T Bronson; Eric S Martin; Philip N Tsichlis; Kenneth E Hung
Journal:  Cancer Lett       Date:  2014-02-24       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.